gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IRDHealthcarePharmaceuticals

Opus Genetics, Inc. Common Stock (IRD)

$3.70+0.82%
Close Nov 2, 2026 · split-adjusted
Oct 30, 2026$3.67▲ 59.57% in range
Oct 31, 2025Low $1.74 · High $6.07Oct 30, 2026
What changed · written from our data
As of Nov 2, 2026

Opus Genetics closed at $3.70 on Nov 2, up 0.82%, 39.0% below its 52-week closing high. Volume of 878.2K shares was 0.57× its 20-day average (below normal).

Split-adjusted performance: -19.2% over one month, -29.1% over six months, +87.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $755K, down 73.8% from a year earlier, with a net margin of -1072.6%.

Short interest was 13.3M shares at the Oct 15 settlement, up 2.5% from the prior report (21.4% of float, 7.4 days to cover).

Market cap$307.8M83.2M shares
Revenue · quarter$755.0K−73.8% YoY
Diluted EPS$-0.14—
P/E · TTM—P/S 31.2×
Net margin-1,072.6%Gross 100.0%
Dividend yieldNone
52-week range1.74 – 6.07−39.0% from high
Volume878.2K0.57× 20-day avg
Volatility · 60d91.9%Annualised
Short % of float21.4%7.4 days to cover
Net cash$53.9MCash $88.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +11.4%1M −19.2%3M −0.3%6M −29.1%YTD +84.1%1Y +87.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum47
Revenue growth17
Net margin20
Value (low P/E)—
Size55

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →
Shares short13.3M+2.5% vs prior
Days to cover7.4Settled Oct 15
% of float21.4%
Short vol. 10d58.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IRDOpus Genetics$3.70+0.82%−29.1%−73.8%−1072.6%—$307.8M
VOGXVogenx$20.74+2.42%————$308.1MCompare
PRLDPrelude Therapeutics Incorporated$3.84−1.03%−19.0%—−244.1%—$306.4MCompare
ENTAEnanta Pharmaceuticals$10.43−2.61%−28.3%−21.6%−135.8%—$303.8MCompare
SPRYARS Pharmaceuticals$3.05−9.76%−65.5%+114.2%−185.2%—$303.3MCompare
BNTCBenitec Biopharma$8.49−2.86%−30.3%———$296.2MCompare
TTRXTurn Therapeutics$9.65−7.48%+160.1%———$293.0MCompare
AVIRAtea Pharmaceuticals$4.10−0.24%−28.1%———$328.8MCompare
CGCCanopy Growth$0.6808+4.34%−38.1%+7.8%−18.0%—$288.0MCompare

News about Opus Genetics

All news →
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaGlobeNewswire Inc. · Oct 16, 2026▲ PositiveOpus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology ConferencesGlobeNewswire Inc. · Sep 2, 2026▲ PositiveOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseGlobeNewswire Inc. · Jul 6, 2026▲ PositiveOpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsGlobeNewswire Inc. · Jun 2, 2026▲ PositiveOpus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswire Inc. · May 27, 2026Neutral

Quick answers

What does Opus Genetics do?
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK.
What is IRD's market cap?
$307.82M, based on the Nov 2 close of $3.70.
Does Opus Genetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IRD is sold short?
13.3M shares, 21.4% of float, as of Oct 15, 2026.
What sector is IRD in?
Healthcare, in the Pharmaceuticals industry.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

HQ: Durham, NC28 employeesListed Nov 6, 2020opusgtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology